|Videos|February 7, 2023
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
Author(s)Loretta J. Nastoupil, MD, Marc S. Hoffmann, MD
Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.
Advertisement
Episodes in this series
Advertisement
Related to this article
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across 3 cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Dostarlimab monotherapy produced a 27% response rate in PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
5